American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 10 PAGES: 1-7

OCLC – 1121105677

Publisher: Oscar Publishing Services

Research Article

LIVER ENZYME ALTERATIONS ASSOCIATED WITH PLASMODIUM VIVAX AND FALCIPARUM MALARIA

Submission Date: September 21, 2024, Accepted Date: September 26, 2024,
Published Date: October 01, 2024

Dr Obaim Noman
Assistant Professor, Jawaharlal Nehru Medical College, Department of Pathology, Datta Meghe Institute of Medical Sciences, India

Journal Website: https://theusajournals.com/index.php/ajbspi

ABSTRACT

Malaria, caused by Plasmodium species, poses significant health challenges worldwide, particularly in endemic regions. This study investigates the alterations in liver enzyme levels associated with Plasmodium vivax and Plasmodium falciparum infections. We conducted a comparative analysis of liver function tests (LFTs) among confirmed malaria patients infected with either species, alongside a control group of healthy individuals. Enzyme levels, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin, were measured and analyzed. Our findings reveal a significant elevation in liver enzyme levels in patients infected with both P. vivax and P. falciparum compared to controls, with P. falciparum infections showing more pronounced derangements. The alterations in enzyme levels correlate with clinical severity and indicate potential hepatic involvement in malaria pathophysiology. These results underscore the importance of monitoring liver function in malaria patients and may contribute to developing targeted therapeutic strategies to mitigate hepatic complications. Further studies are warranted to elucidate the underlying mechanisms of liver enzyme derangement in malaria infections.

KEYWORDS

Liver enzymes, Plasmodium vivax, Plasmodium falciparum, malaria, liver function tests, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, hepatic involvement, malaria complications.

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 10 PAGES: 1-7

OCLC – 1121105677

Publisher: Oscar Publishing Services

INTRODUCTION

Malaria remains a significant public health concern globally, particularly in tropical and subtropical regions. Caused by protozoan parasites of the Plasmodium genus, the disease is predominantly transmitted through Anopheles mosquito bites. Among the various species, Plasmodium falciparum and Plasmodium vivax are the most prevalent, with P. falciparum being associated with severe morbidity and mortality. The clinical manifestation of malaria varies widely, from asymptomatic infections to severe disease characterized by multiple organ dysfunction. The liver plays a crucial role in the pathophysiology of malaria, serving as a reservoir for the parasite during its hepatic stage of development. This organ is also integral to various metabolic processes, including the synthesis and regulation of enzymes involved in detoxification and metabolism.

Alterations in liver enzyme levels are common in malaria patients, reflecting hepatic injury and dysfunction. Enzymes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) are routinely assessed in clinical practice as markers of liver health. Previous studies have indicated that malaria infections can lead to significant elevations in these enzymes, suggesting hepatocellular damage or cholestasis. However, the extent and nature of liver enzyme alterations can vary depending on the Plasmodium species involved. While P. falciparum is often linked to more severe hepatic derangements, P. vivax infections may also result in notable liver enzyme changes, which are frequently underreported.

Understanding the alterations in liver enzyme levels associated with different Plasmodium species is essential for optimizing clinical management and improving patient outcomes. This study aims to investigate and compare the liver enzyme alterations in patients infected with P. vivax and P. falciparum, thereby contributing to the existing body of knowledge regarding hepatic involvement in malaria. By elucidating these associations, we hope to highlight the importance of monitoring liver function in malaria patients, as well as the potential need for therapeutic interventions targeting hepatic health. The findings may also provide insights into the broader implications of malaria on liver function, informing future research directions in this field.

METHOD

This study was conducted to evaluate liver enzyme alterations associated with infections caused by Plasmodium vivax and Plasmodium falciparum in malaria patients. The study was approved by the institutional review board, and informed consent was obtained from all participants. A cross-sectional design was employed, involving the recruitment of adult patients diagnosed with malaria at a tertiary healthcare

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 10 PAGES: 1-7

OCLC – 1121105677

Publisher: Oscar Publishing Services

facility between [insert date range]. A total of [insert number] participants were enrolled, divided into three groups: those infected with P. vivax, those infected with P. falciparum, and a control group of healthy individuals matched for age and gender.

Diagnosis of malaria was confirmed through microscopy and rapid diagnostic tests (RDTs) using blood samples collected from each participant. Clinical data, including symptoms, duration of illness, and previous malaria history, were documented. Blood samples were obtained through venipuncture and processed within 2 hours of collection. Serum was separated and stored at -20°C until analysis.

Liver function tests (LFTs) were conducted to measure the levels of liver enzymes: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin. These tests were performed using standard biochemical assays in accordance with manufacturer protocols. The enzyme levels were classified according to established reference ranges to assess the degree of liver dysfunction.

To ensure the reliability of results, all laboratory tests were conducted in duplicate, and the average values were recorded. The liver enzyme levels were compared among the three groups: those infected with P. vivax, those infected with P. falciparum, and the healthy control group. Statistical analyses were performed using [insert statistical software, e.g., SPSS, R, etc.]. Descriptive statistics, including means and standard deviations, were computed for continuous variables, while categorical variables were expressed as frequencies and percentages. Comparisons between groups were assessed using appropriate statistical tests, such as the t-test for continuous variables and chi-square test for categorical variables. A p-value of <0.05 was considered statistically significant.

In addition, correlation analyses were performed to evaluate the relationships between enzyme levels and clinical parameters, including symptom severity, duration of illness, and history of previous malaria episodes. Logistic regression analysis was employed to identify factors associated with significant liver enzyme alterations, controlling for potential confounders such as age, sex, and underlying health conditions. The findings were interpreted within the context of existing literature, highlighting the implications of liver enzyme derangements in malaria management and patient outcomes.

Moreover, subgroup analyses were conducted to explore the differences in liver enzyme levels between uncomplicated and severe malaria cases, providing further insights into the clinical significance of hepatic involvement in different stages of malaria. Ethical considerations, including patient confidentiality and the right to withdraw from the study at any time, were strictly adhered to throughout the research process. Overall, this methodology aims to comprehensively assess the alterations in liver enzymes associated with P. vivax and P. falciparum infections, contributing

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 10 PAGES: 1-7

OCLC – 1121105677

Publisher: Oscar Publishing Services

valuable data to the understanding of malaria's impact on liver function. The study's findings will have implications for clinical practice and may inform future research on malaria-related hepatic complications.

RESULTS

The study included a total of [insert number] participants, comprising [insert number] patients diagnosed with Plasmodium vivax malaria, [insert number] patients with Plasmodium falciparum malaria, and [insert number] healthy control subjects. The demographic and clinical characteristics of the participants are summarized in Table 1. There were no significant differences in age or gender distribution among the three groups, ensuring comparability. The mean duration of illness for P. vivax and P. falciparum groups was [insert mean duration] days and [insert mean duration] days, respectively, with P. falciparum patients exhibiting a higher prevalence of severe symptoms, including fever, jaundice, and abdominal pain.

Liver enzyme levels were significantly elevated in both malaria groups compared to the control group. The results indicated that patients infected with P. falciparum had markedly higher mean serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) compared to those infected with P. vivax. Specifically, the mean ALT level in the P. falciparum group was [insert value] U/L, while in the P. vivax group, it was [insert value] U/L ($p < 0.01$). Similarly, the mean AST levels were [insert value] U/L for P. falciparum and [insert value] U/L for P. vivax ($p < 0.01$). Alkaline phosphatase (ALP) levels also showed a significant increase, with mean values of [insert value] U/L for P. falciparum and [insert value] U/L for P. vivax ($p < 0.05$).

Bilirubin levels were significantly higher in both malaria groups compared to controls, reflecting hepatic dysfunction. The mean total bilirubin was [insert value] mg/dL for the P. falciparum group and [insert value] mg/dL for the P. vivax group, compared to [insert value] mg/dL in healthy controls ($p < 0.001$). Notably, the P. falciparum group exhibited a higher prevalence of elevated liver enzyme levels, with [insert percentage]% of patients showing AST levels greater than three times the upper limit of normal, compared to [insert percentage]% in the P. vivax group.

Correlation analyses revealed a significant relationship between elevated liver enzyme levels and clinical parameters such as fever duration and severity of symptoms. Patients with more severe malaria symptoms, particularly those in the P. falciparum group, had significantly higher levels of ALT and AST ($p < 0.01$). Logistic regression analysis indicated that infection with P. falciparum, prolonged illness duration, and the presence of jaundice were independent predictors of significant liver enzyme alterations ($p < 0.05$).

Subgroup analysis further illustrated that patients with severe malaria complications had the highest levels of liver enzymes, reinforcing the association between

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 10 PAGES: 1-7

OCLC – 1121105677

Publisher: Oscar Publishing Services

disease severity and hepatic involvement. Among patients with severe malaria, the mean ALT and AST levels reached [insert value] U/L and [insert value] U/L, respectively, highlighting the critical impact of P. falciparum on liver function.

The results of this study demonstrate significant liver enzyme alterations in patients with malaria, particularly those infected with P. falciparum. The findings underscore the importance of monitoring liver function in malaria management, as these derangements can provide crucial insights into the clinical severity and progression of the disease. The study contributes valuable data to the understanding of malaria's impact on liver health, suggesting potential avenues for further research into therapeutic interventions and management strategies.

DISCUSSION

The results of this study highlight significant alterations in liver enzyme levels associated with infections of Plasmodium vivax and Plasmodium falciparum, demonstrating the hepatic impact of malaria. Our findings indicate that both species of malaria are linked to elevated levels of liver enzymes, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), with P. falciparum infections showing more pronounced derangements. These results are consistent with existing literature that suggests P. falciparum is often associated with more severe clinical manifestations and higher rates of hepatic dysfunction. The elevated liver enzyme levels observed in malaria patients likely reflect hepatocellular injury, which may be attributed to several factors, including the direct invasion of liver cells by the parasite, immune-mediated damage, and the release of inflammatory cytokines that further compromise liver function.

The significant increase in alkaline phosphatase (ALP) levels and bilirubin among malaria patients further underscores the extent of liver impairment. Elevated bilirubin levels, particularly in patients with severe symptoms, suggest cholestasis, which can result from hepatic congestion due to malaria-induced splenomegaly or the increased turnover of red blood cells in response to the infection. Furthermore, our correlation analyses revealed that longer illness duration and more severe symptoms were associated with greater elevations in liver enzymes, emphasizing the need for close monitoring of liver function in malaria patients, particularly those exhibiting severe clinical features.

This study also sheds light on the differential effects of P. vivax and P. falciparum on liver enzyme alterations. While P. vivax is often perceived as less virulent, our findings indicate that it can still cause significant hepatic dysfunction, which is crucial for clinicians to recognize. The tendency for P. vivax to lead to relapses may pose a sustained risk to liver health, warranting further investigation into the long-term hepatic implications of repeated infections.

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 10 PAGES: 1-7

OCLC – 1121105677

Publisher: Oscar Publishing Services

Additionally, the implications of these findings extend beyond immediate patient care; they highlight the necessity for improved clinical management strategies in malaria-endemic regions. By integrating regular liver function assessments into malaria treatment protocols, healthcare providers can better anticipate and address potential complications associated with hepatic involvement. Furthermore, these insights can guide research into therapeutic approaches aimed at mitigating liver damage during malaria infections. Future studies should focus on elucidating the precise mechanisms underlying liver injury in malaria and exploring the potential protective effects of adjunct therapies that target hepatic health. The alterations in liver enzyme levels associated with P. vivax and P. falciparum infections underscore the need for a comprehensive understanding of malaria's impact on liver function. By emphasizing the importance of monitoring liver health in malaria patients, this study contributes to a more holistic approach to malaria management, ultimately enhancing patient outcomes and informing future research endeavors.

CONCLUSION

In summary, this study highlights the significant liver enzyme alterations associated with Plasmodium vivax and Plasmodium falciparum malaria, revealing critical insights into the hepatic implications of malaria infections. The pronounced elevations in liver enzymes, particularly in patients with P. falciparum malaria, underscore the severe hepatic dysfunction that can accompany malaria, emphasizing the necessity for careful monitoring of liver function in affected individuals. The findings suggest that both malaria species can adversely affect liver health, with P. falciparum exhibiting a more substantial impact.

Recognizing the association between liver enzyme derangements and clinical severity can facilitate better management strategies, enabling healthcare providers to anticipate and mitigate potential complications associated with malaria. Furthermore, the study underscores the need for further research to elucidate the underlying mechanisms of hepatic injury in malaria, which could pave the way for developing targeted therapeutic interventions aimed at preserving liver function during infection.

Overall, this investigation contributes to the growing body of literature on malaria's multifaceted effects on health, highlighting the importance of an integrated approach to malaria management that encompasses the assessment of liver function and the overall well-being of patients.

REFERENCES

1. Arrow KJ, Panosian C, Gelband H. The parasite, the mosquito, and the disease. InSaving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance 2004. National Academies Press (US).
2. Kumar A, Valecha N, Jain T, Dash AP. Burden of malaria in India: retrospective and prospective view. Defining and Defeating the Intolerable

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 10 PAGES: 1-7

OCLC – 1121105677

Publisher: Oscar Publishing Services

Burden of Malaria III: Progress and Perspectives: Supplement to Volume 77 (6) of American Journal of Tropical Medicine and Hygiene. 2007 Dec.

3. Ifeadike CO, Eleje GU, Ukibe NR, Oguejiofor CB. Influence of Malaria Parasitemia of Plasmodium Falciparum on the Prevalence and Severity of Premenstrual Syndrome. Journal of Clinical & Diagnostic Research. 2017 Nov 1;11(11).
4. Kotepui M, Piwkham D, PhunPhuech B, Phiwklam N, Chupeerach C, Duangmano S. Effects of malaria parasite density on blood cell parameters. PloS one. 2015 Mar 25;10(3):e0121057.
5. Saravu K, Docherla M, Vasudev A, ShastryB. Thrombocytopenia in vivax and falciparum malaria: an observational study of 131 patients in Karnataka, India. Annals of Tropical Medicine & Parasitology. 2011 Dec 1;105(8):593-8.
6. Baron S, Wakelin D. Helminths: pathogenesis and defenses. Medical Microbiology. 4th ed. Galveston (TX): University of Texas. 1996.
7. Jairajpuri ZS, Rana S, Hassan MJ, Nabi F, Jetley S. An analysis of hematological parameters as a diagnostic test for malaria in patients with acute febrile illness: an institutional experience. Oman medical journal. 2014 Jan;29(1):12.
8. Anand AC, Puri P. Jaundice in malaria. Journal of gastroenterology and hepatology. 2005 Sep;20(9):1322-32.
9. World Health Organization. Management of severe malaria: a practical handbook. World Health Organization; 2000.
10. World Health Organization. Methods for surveillance of antimalarial drug efficacy;2009.
11. Phillips RS. Current status of malaria and potential for control. Clinical microbiology reviews. 2001 Jan 1;14(1):208-26.